Increased Soluble Thrombomodulin in Hemodialysis Patients with Long-term Erythropoietin Treatment: What Does it Reflect?

1. Borawski J , Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost 2002;8:77-77.

2. Borawski J , Naumnik B , Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: Associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost 2002;8:359-359.

3. Borawski J , Naumnik B , Mysliwiec M. Increased soluble thrombomodulin does not always indicate endothelial injury. Clin Appl Thromb Hemost 2002;8:87-87.

4. Borawski J , Naumnik B , Pawlak K , et al. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in hemodialyzed patients. Nephrol Dial Transplant 2001;16:787-787.

5. Tomura S , Nakamura Y , Deguchi F , et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing hemodialysis therapy. Thromb Res 1990;58:413-413.

6. Nakamura Z , Tomura S , Tochibana , et al. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992;38:90-90.

7. Stasko J , Funiak S , Funiakova S , et al. Erythropoietin, thrombomodulin, factor von Willebrand and hemodialysis. Rev Iberoam Tromb Hemostasia 1995;8:134-134.

8. Borawski J , Naumnik B , Pawlak K , et al. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001;16:1442-1442.

9. Malyszko JS , Malyszko J , Pawlak K , et al. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron 2000;84:305-305.

10. Aguilera A , Selgas R , Ruiz-Caravaca ML , et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int 1999;19:161-161.

11. Clyne N , Egberg N , Lins LE . Effects of hemodialysis and longterm erythropoietin treatment on protein C and on free and total protein S. Thromb Res 1995;80:161-161.

12. Dufourcq P , Seigneur M , Pruvost A , et al. Membrane thrombomodulin levels are decreased during hypoxia and restored by cAMP and IBMX. Thromb Res 1995;77:305-305.

13. Kuriyama S , Hopp L , Yoshida H , et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hematol 1996;9:426-426.

14. Stagko J , Galajda P , Hudesek J , et al. Increased soluble thrombomodulin in dialysed patients treated with erythropoietin a role of reduced hypoxia? Thromb Hemost 2001 [suppl on CD/ROM, abstract of the XVIII ISTH Congress]:P2858-P2858.